JS212

DRUG3 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Esophageal Squamous Cell CarcinomaMetastatic Colorectal CancerNon-squamous Non-small Cell Lung Cancer

Phase 2

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

RecruitingNCT06868836

Shanghai Junshi Bioscience Co., Ltd.Non-squamous Non-small Cell Lung Cancer

Start: 2025-03-30End: 2028-04-04Target: 78Updated: 2026-05-18

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT07484724

Shanghai Junshi Bioscience Co., Ltd.Advanced Esophageal Squamous Cell Carcinoma

Start: 2026-04-13End: 2028-04-01Target: 280Updated: 2026-04-22

JS212 Combination Therapies in Metastatic Colorectal Cancer

RecruitingNCT07503756

Shanghai Junshi Bioscience Co., Ltd.Metastatic Colorectal Cancer

Start: 2026-04-25End: 2028-03-30Target: 80Updated: 2026-05-05